Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Advanced Therapy Medicinal Products Market by Therapy Type (Cell Therapy, CAR T Therapy, Gene Therapy, Tissue Engineered Product), by Application (Oncology, Neurology, Autoimmune disorders, Others) and by End User (Hospitals, Cancer Treatment Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13332

Pages: NA

Charts: NA

Tables: NA

Advanced therapy medicinal products are modern therapies that include cell therapy, tissue engineered products, and gene therapy. This advance therapy provides solutions for condition with no therapeutic alternatives. Cell therapy incorporate with cellular immunotherapies, autologous, and allogeneic cells for specific therapeutic conditions. Gene therapy refers to products that add genetic material into individuals DNA to replace faulty genetic material. Tissue engineered products refers to repair, regenerate, and replace human tissue. Advanced therapy medicinal products which influences living cell or dynamic hereditary materials to offer novel treatment for intense and constant infections.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the advanced therapy medicinal products market.

Top Impacting Factors

  • Rise in cases of Alzheimer’s diseases across the globe, rise in demand for advance gene therapies, surge in prevalence of neurodegenerative diseases, rise in geriatric population, and  increase in genetic disorders are the key factors that drive the growth of advanced therapy medicinal products market.
  • In addition, grow in adaptation of highly advanced therapy methods, surge in demand for minimally invasive products, increase in consumer demands, surge in expenses on healthcare sector, R&D activities to improve quality of drug, launch of novel drugs, and joint ventures, collaboration, & mergers between local & key market players are expected to boost the growth of market.
  • However, high cost of treatment procedures and lack of awareness regarding advance therapy can hinder the growth of market.
  • Contrarily, grow in demand for cellular immunotherapies and favourable government policies are expected to offer lucrative opportunities for the expansion of the market.

Market Trend

New Product Launches to Flourish the Market

In 2020 Rigenerand announced approval for manufacturing of RR001 by Italian Medicine Authority. RR001 is gene therapy product consist of autologous human adipose derived genetically modified cells.

In June 2019, bluebird bio has received marketing authorization from European Commission for launch of ZYNTEGLO. This product is use in gene therapy for patients 12 years and older with Transfusion-Dependent β-Thalassemia. ZYNTEGLO is the first known gene therapy medication approved for transfusion-dependent β-thalassemia.

Key Benefits of the Report

  • This study presents the analytical depiction of advanced therapy medicinal products market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Advanced Therapy Medicinal Products Market Report        

  • Which are the leading players active in the advanced therapy medicinal products market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "advanced therapy medicinal products"?
  • What is "advanced therapy medicinal products" market prediction in the future?
  • Who are the leading global players in the "advanced therapy medicinal products" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "advanced therapy medicinal products" market report?

 Key Market Segments

  • By Therapy Type
    • Cell Therapy
      • by Type
        • Stem Cell
        • Non stem Cell
    • CAR T Therapy
    • Gene Therapy
    • Tissue Engineered Product
  • By Application
    • Oncology
    • Neurology
    • Autoimmune disorders
    • Others
  • By End User
    • Hospitals
    • Cancer Treatment Centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bluebird Bio, Inc.
  • NUVASIVE, INC.
  • MESOBLAST LTD
  • Stemedica Cell Technologies, Inc.
  • KOLON TISSUEGENE, INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • Novartis AG
  • Gilead Sciences
  • ALLOSOURCE
  • MEDIPOST CO., LTD.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY THERAPY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Type

    • 4.2. Cell Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Type

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Stem Cell

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Non stem Cell

          • 4.2.4.2.1. Market Size and Forecast

    • 4.3. CAR T Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gene Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Tissue Engineered Product

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Neurology

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Autoimmune Disorders

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cancer Treatment Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapy Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Advanced Therapy Medicinal Products Market

        • 7.2.6.1. Market Size and Forecast, By Therapy Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Advanced Therapy Medicinal Products Market

        • 7.2.7.1. Market Size and Forecast, By Therapy Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Advanced Therapy Medicinal Products Market

        • 7.2.8.1. Market Size and Forecast, By Therapy Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapy Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Advanced Therapy Medicinal Products Market

        • 7.3.6.1. Market Size and Forecast, By Therapy Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Advanced Therapy Medicinal Products Market

        • 7.3.7.1. Market Size and Forecast, By Therapy Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Advanced Therapy Medicinal Products Market

        • 7.3.8.1. Market Size and Forecast, By Therapy Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Advanced Therapy Medicinal Products Market

        • 7.3.9.1. Market Size and Forecast, By Therapy Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Advanced Therapy Medicinal Products Market

        • 7.3.10.1. Market Size and Forecast, By Therapy Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Advanced Therapy Medicinal Products Market

        • 7.3.11.1. Market Size and Forecast, By Therapy Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Advanced Therapy Medicinal Products Market

        • 7.3.12.1. Market Size and Forecast, By Therapy Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapy Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Advanced Therapy Medicinal Products Market

        • 7.4.6.1. Market Size and Forecast, By Therapy Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Advanced Therapy Medicinal Products Market

        • 7.4.7.1. Market Size and Forecast, By Therapy Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Advanced Therapy Medicinal Products Market

        • 7.4.8.1. Market Size and Forecast, By Therapy Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Advanced Therapy Medicinal Products Market

        • 7.4.9.1. Market Size and Forecast, By Therapy Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Advanced Therapy Medicinal Products Market

        • 7.4.10.1. Market Size and Forecast, By Therapy Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Advanced Therapy Medicinal Products Market

        • 7.4.11.1. Market Size and Forecast, By Therapy Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Advanced Therapy Medicinal Products Market

        • 7.4.12.1. Market Size and Forecast, By Therapy Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Advanced Therapy Medicinal Products Market

        • 7.4.13.1. Market Size and Forecast, By Therapy Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Advanced Therapy Medicinal Products Market

        • 7.4.14.1. Market Size and Forecast, By Therapy Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapy Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Advanced Therapy Medicinal Products Market

        • 7.5.6.1. Market Size and Forecast, By Therapy Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Advanced Therapy Medicinal Products Market

        • 7.5.7.1. Market Size and Forecast, By Therapy Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Advanced Therapy Medicinal Products Market

        • 7.5.8.1. Market Size and Forecast, By Therapy Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Advanced Therapy Medicinal Products Market

        • 7.5.9.1. Market Size and Forecast, By Therapy Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Advanced Therapy Medicinal Products Market

        • 7.5.10.1. Market Size and Forecast, By Therapy Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Advanced Therapy Medicinal Products Market

        • 7.5.11.1. Market Size and Forecast, By Therapy Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bluebird Bio, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Novartis AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. KOLON TISSUEGENE, INC.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. ALLOSOURCE

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. MEDIPOST CO., LTD.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. NUVASIVE, INC.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Stemedica Cell Technologies, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. JCR PHARMACEUTICALS CO., LTD.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. MESOBLAST LTD

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Gilead Sciences

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CELL THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CAR T THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR GENE THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR TISSUE ENGINEERED PRODUCT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR NEUROLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA ADVANCED THERAPY MEDICINAL PRODUCTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. BLUEBIRD BIO, INC.: KEY EXECUTIVES
  • TABLE 108. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
  • TABLE 109. BLUEBIRD BIO, INC.: OPERATING SEGMENTS
  • TABLE 110. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
  • TABLE 111. BLUEBIRD BIO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 113. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 114. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 115. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 116. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. KOLON TISSUEGENE, INC.: KEY EXECUTIVES
  • TABLE 118. KOLON TISSUEGENE, INC.: COMPANY SNAPSHOT
  • TABLE 119. KOLON TISSUEGENE, INC.: OPERATING SEGMENTS
  • TABLE 120. KOLON TISSUEGENE, INC.: PRODUCT PORTFOLIO
  • TABLE 121. KOLON TISSUEGENE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. ALLOSOURCE: KEY EXECUTIVES
  • TABLE 123. ALLOSOURCE: COMPANY SNAPSHOT
  • TABLE 124. ALLOSOURCE: OPERATING SEGMENTS
  • TABLE 125. ALLOSOURCE: PRODUCT PORTFOLIO
  • TABLE 126. ALLOSOURCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. MEDIPOST CO., LTD.: KEY EXECUTIVES
  • TABLE 128. MEDIPOST CO., LTD.: COMPANY SNAPSHOT
  • TABLE 129. MEDIPOST CO., LTD.: OPERATING SEGMENTS
  • TABLE 130. MEDIPOST CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 131. MEDIPOST CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. NUVASIVE, INC.: KEY EXECUTIVES
  • TABLE 133. NUVASIVE, INC.: COMPANY SNAPSHOT
  • TABLE 134. NUVASIVE, INC.: OPERATING SEGMENTS
  • TABLE 135. NUVASIVE, INC.: PRODUCT PORTFOLIO
  • TABLE 136. NUVASIVE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. STEMEDICA CELL TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 138. STEMEDICA CELL TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 139. STEMEDICA CELL TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 140. STEMEDICA CELL TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 141. STEMEDICA CELL TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. JCR PHARMACEUTICALS CO., LTD.: KEY EXECUTIVES
  • TABLE 143. JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT
  • TABLE 144. JCR PHARMACEUTICALS CO., LTD.: OPERATING SEGMENTS
  • TABLE 145. JCR PHARMACEUTICALS CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 146. JCR PHARMACEUTICALS CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. MESOBLAST LTD: KEY EXECUTIVES
  • TABLE 148. MESOBLAST LTD: COMPANY SNAPSHOT
  • TABLE 149. MESOBLAST LTD: OPERATING SEGMENTS
  • TABLE 150. MESOBLAST LTD: PRODUCT PORTFOLIO
  • TABLE 151. MESOBLAST LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. GILEAD SCIENCES: KEY EXECUTIVES
  • TABLE 153. GILEAD SCIENCES: COMPANY SNAPSHOT
  • TABLE 154. GILEAD SCIENCES: OPERATING SEGMENTS
  • TABLE 155. GILEAD SCIENCES: PRODUCT PORTFOLIO
  • TABLE 156. GILEAD SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET
  • FIGURE 3. SEGMENTATION ADVANCED THERAPY MEDICINAL PRODUCTS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ADVANCED THERAPY MEDICINAL PRODUCTS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALADVANCED THERAPY MEDICINAL PRODUCTS MARKET
  • FIGURE 11. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION, BY BY THERAPY TYPE
  • FIGURE 12. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CELL THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CAR T THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR GENE THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR TISSUE ENGINEERED PRODUCT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR NEUROLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. ADVANCED THERAPY MEDICINAL PRODUCTS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: ADVANCED THERAPY MEDICINAL PRODUCTS MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. BLUEBIRD BIO, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. BLUEBIRD BIO, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. BLUEBIRD BIO, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. KOLON TISSUEGENE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. KOLON TISSUEGENE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. KOLON TISSUEGENE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. ALLOSOURCE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. ALLOSOURCE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. ALLOSOURCE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. MEDIPOST CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. MEDIPOST CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. MEDIPOST CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. NUVASIVE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. NUVASIVE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. NUVASIVE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. STEMEDICA CELL TECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. STEMEDICA CELL TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. STEMEDICA CELL TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. JCR PHARMACEUTICALS CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. JCR PHARMACEUTICALS CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. JCR PHARMACEUTICALS CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. MESOBLAST LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. MESOBLAST LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. MESOBLAST LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. GILEAD SCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. GILEAD SCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. GILEAD SCIENCES: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Advanced Therapy Medicinal Products Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved